Edesa Biotech Inc (EDSA) COM NPV
Edesa Biotech Inc., Stellar Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for dermatological and gastrointestinal indications. The Company’s lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis. The Company has its operations in the United States and in Canada.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.